Download GI bleeding

Survey
yes no Was this document useful for you?
   Thank you for your participation!

* Your assessment is very important for improving the work of artificial intelligence, which forms the content of this project

Document related concepts
no text concepts found
Transcript
GI bleeding
GI bleeding
„
Term:
Hematemesis : bloody vomitus
Melena: tarry stool passage
Maroon : tarry- bloody stool
passage
Hematochezia: bloody stool
passage
1
GI bleeding
„
„
„
„
„
Bleeding > 5~10ml
Æ OB (+)
Bleeding > 50~100ml
Æ tarry stool
Bleeding above Treitz lig.Æ hematemesis
Bleeding above ileocecal valve Æ tarry
stool
Bleeding below ileocecal valve Æ fresh
bloody stool
1. R’t side colon Æ blood mixed inside
the stool
2. L’t side colon Æ blood coated outside
the stool
3.rectosigmoid Æ fresh bloody discharge
Common cause of acute UGI
bleeding
„
„
„
„
„
„
„
Erosive, hemorrhagic gastropathy ( aspirin,
other NSAIDs) (3~11%)
Ulcer: Gastric or duodenal ulcer (35~62%)
Mallory-Weiss tear (4~13%)
Varices – portal hypertensive
gastropathy(4~31%)
Arteriovenous malformation
Maligancy (1~4%)
No source identified ( 7~25%)
2
Common cause of acute LGI
bleeding
„
1.
2.
3.
4.
5.
< 55 y/o
Anorectal disease
( hemorrhoid,
fissures)
Colitis (IBD,
infection)
Diverticulosis
Polys, cancer
Angiodysplasia
„
1.
2.
3.
4.
5.
> 55 y/o
Anorectal disease
(hemorrhoid, fissures)
Diverticulosis
Angiodysplasia
Polys, cancer
Enterocolitic
(ischemic, infection,
IBD, radiation)
Evaluated blood loss
Blood loss %
(ml)
BP
HR
S/S
0~500
0~10%
No change
No change None
500~1000
10~20%
<120bpm
Peripheral
cool
1000~1750
20~35%
Posture
hypotension
90<SBP<120
>120bpm
+oliguria
>1750
>35%
SBP<90
<60bpm
+ shock
3
Peptic ulcer
„
Phase of GU, DU
Active stage:
A1: well-defined, deep ulceration;
marked bleeding from the ulcer base
marginal welling
A2: stop bleeding
Healing stage (H): H1,H2,H3
Scarred stage (S): S1( red scar), S2(white
scar)
Forrest Grade I
4
Forrest Grade
IIA
IIB
Forrest Grade
IIC
III
5
Peptic ulcer
„
„
Risk of recurrent bleeding
SRH: stigmata of recent hemorrhage
exposure vessels
adherent clots
arterial spurting or oozing
Endoscopic therapy
HSE (hypertonic saline and epinephrine),
bipolar electrocoagulation, heat probe,
hematoclip, APC
Risk factors
„
„
„
„
„
„
„
„
„
> 60 y/o age
More than one comorbid illness
Blood loss > 5 units
Shock on admission
Bright-red hematemesis with hypotension
Coagulopathy
Large ( > 2cm) ulcer
Recurrent hemorrrhage ( within 72 hrs)
Requirement for emergency surgery
6
GI bleeding – goals of
management
„
„
„
Hemodynamic stable
Active bleeding stopped
Recurrent bleeding prevented
Hemodynamic stable
„
„
„
„
„
Pulse pressure > 30 mmHg
SBP > 110 mmHg
DBP > 70 mmHg
HR < 100 bpm
Good skin turgor
7
UGI bleeding -- management
„
„
Restoration of intravascular volume
Hct: > 25%
Hct: > 30% in cardiac or pulmonary dz
Æ Vasopressors indicated ?
Vol resuscitation end-point
CVP=15 mmHg
Wedge pressure = 10 to 12 mmHg
Blood lactate < 4 mmol/ L
Base deficit –3 to +3 mmol/L
C.I. > 3L/min/m2
UGI bleeding -- management
„
„
O2 consumption ( V O2) = Q * Hb *
(SaO2-SvO2)
Volume deficit = % loss * normal blood
volume
Males – 70 ml / kg or 3.2 L/ M2
Females – 60 ml / kg or 2.9 L/ M2
8
UGI bleeding -- management
„
„
Correction of coagulopathy
Initial infusion: FFP 2~4 u
Protamine infusion ( 1mg antagonizes
=100 u of heparin)
Vit-K (10 mg,IM): warfarin, hepatobiliary
disease
PLT transfusion: > 50000/cumm
Airway protection
PUD-- treatment
Antacids
drug interaction – Tetracyclines,
Quinolone, ketoconazole,
„ Peptic ulcer ( with evidence)
H2-blocker: Ranitidine (Zantac, Quicran)
side effect: headache, lethargy, confusion,
depression
drug interaction: Cimetidine Æ
β-blockers, Metformin, Phenytoin, Procainamide,
Theophylline, TCA and Warfarin.
„
9
PUD -- treatment
„
„
„
Peptic ulcer ( with evidence)
PPIs: Omeprazole ( Losec)
-- elder
-- intractable bleeding
-- combine with theophylline
Raise intragastric pH to 6~7
Enhance clot stablity decreased further
bleeding (but not mortality)
UGI bleeding -- treatment
„
Variceal hemorrhage
1. Stabilize hemodynamic ( crystal with colloid
supply)
2. Airway patent
3. NG decompression of early detect of rebleeding
4. Octreotide: Somatostatine (Somatosan)
2Amp add N/S to 50ml Æ loading 2ml and
maintain 2ml/ hr
10
UGI bleeding -- treatment
„
Variceal hemorrhage
5. Endoscopic therapy with ligation
6. Sclerotherapy
7. Balloon tamponade Sengstaken-Blakemore
tube
8. Avoid hepatic encephalopathy
9. Prophylaxis: reduce portal hypertensoion
-- Inderal, nitrates
10. Surgery
Recurrent bleeding prevented
„
„
Eradication of H.P Æ rebleeding rate < 5%
Avoid NSAIDs
11
acute UGI bleeding
if no hemodynamic change and
no dropping Hb:
routine endoscopy
ulcer
hemodynamic change and
dropping Hb:
urgent endoscopy
EV
active bleeding
or visible vessel
adherent clot or flat
,pigmented spot
Endoscopic therapy
no Endoscopic therapy no Endoscopic therapy ICU for 1~2 day
ward for 2 to 3 days
ICU for 1 day
ward for 1 to 2 days
ward for 3 days
clear base
discharge
ligation or
sclerotherapy
Mallory-Weiss tear
active bleeding
no active bleeding
Endoscopic therapy
no Endoscopic therapy
ward for 1~2 days
discharge
12
Related documents